Literature DB >> 15701504

Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma.

Kwang Cheol Koh1, Hyuk Lee, Moon Seok Choi, Joon Hyoek Lee, Seung Woon Paik, Byung Chul Yoo, Jong Chul Rhee, Jae Won Cho, Cheol Keun Park, Hong Joo Kim.   

Abstract

BACKGROUND: Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma (HCC-CC) have not been established.
METHODS: Data of patients who underwent surgical resection for HCC-CC were compared with those of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CC) patients.
RESULTS: The prevalence of hepatitis B positivity (54.0%) and that of cirrhosis (54.2%) in the HCC-CC group were of intermediate tendency between the HCC group and the CC group. The HCC-CC group presented with a higher prevalence of multiplicity and microvascular emboli and portal vein or hepatic vein invasion, but a lower prevalence of capsular formation compared with the other groups. One- and 3-year survival rates in the HCC-CC group (81.9% and 47.0%, respectively) were lower than those in the HCC group and higher than those in the CC group. The cumulative recurrence rates at 6 months and at 1 year in the HCC-CC group (25.0% and 33.3%, respectively) were higher than those in the HCC group and lower than those in the CC group.
CONCLUSIONS: The HCC-CC group has distinct clinicopathologic features compared with the HCC or CC groups. In addition, the HCC-CC group has a prognosis that is better than the CC group but worse than the HCC group.

Entities:  

Mesh:

Year:  2005        PMID: 15701504     DOI: 10.1016/j.amjsurg.2004.03.018

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  62 in total

1.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 2.  Combined hepatocellular and cholangiocarcinoma associated with hepatolithiasis: report of a case.

Authors:  Kemal Deniz; Edip Torun; Mehmet Celikbilek; Erdoğan Sözüer
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

3.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

Review 4.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

5.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

6.  Portal vein occlusion after biliary metal stent placement in hilar cholangiocarcinoma.

Authors:  Kyung Hee Woo; Jin Bae Kim; Yoon Jung Chang; Hyo Jung Kim; Il Hyun Baek; Jin Seok Ko; Ji Young Woo; Hong Dae Kim; Myung Seok Lee
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

7.  Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.

Authors:  Zhen-Feng Wu; Xiao-Yu Wu; Nan Zhu; Zhe Xu; Wei-Su Li; Hai-Bin Zhang; Ning Yang; Xue-Quan Yao; Fu-Kun Liu; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 8.  Hepatic progenitor cells in human liver tumor development.

Authors:  Louis Libbrecht
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

9.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

10.  Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.

Authors:  Hao Wu; Yan Liu; Xiao-Wei Jiang; Wen-Fang Li; Gang Guo; Jian-Ping Gong; Xiong Ding
Journal:  Tumour Biol       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.